Standardized e-cigarette tested against usual brands in nicotine study
NCT ID NCT05658471
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how nicotine is absorbed and affects the body when using a standardized research e-cigarette compared to a person's usual brand e-cigarette. Thirty-two regular e-cigarette users participated in a crossover study where they used both types. Researchers measured nicotine levels in the blood, puffing patterns, and feelings of satisfaction or withdrawal. The goal was to see if the research e-cigarette can be a reliable tool for future studies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- nicotine
- What this could lead to
- If successful, this could help standardize research e-cigarettes for future studies on nicotine exposure and health effects.
- What could go wrong
- This is a small, completed study with only 32 participants, so results may not apply to all e-cigarette users. It does not test long-term health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
32 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy on the basis of medical history and limited physical examination- * Heart rate \< 105 beats per minute (BPM)\*. * Systolic Blood Pressure \< 160 and \> 90\*. * Diastolic Blood Pressure \< 100 and \> 50\*. * \*considered out of range if both machine and manual readings are above/below these thresholds. * Body Mass Index \<= 38.0. * Current regular user of electronic cigarettes (EC) * EC device use at least 15 or more days in the past 30 days (with e- liquid \>= 3mg/ml) * No restriction on flavor or type of e-cigarette used * Saliva cotinine \>= 50 ng/ml and/or NicAlert = 6 * Age \>= 21 years old \<= 70 years old * Willingness to abstain from drug use for the duration of the study Exclusion Criteria: * The following unstable medical conditions: * Heart disease * Seizures * Cancer * Thyroid disease (okay if controlled with medication) * Diabetes * Hepatitis B or C or Liver disease * Glaucoma * Kidney disease or urinary retention * History of stroke * An ulcer in the past year * Active use of an inhaler for Asthma or chronic obstructive pulmonary disease (COPD) * Medications * Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs). * Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers). * Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum). * Any stimulant medications (example: Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment. * Other/Misc. Health Conditions * Oral thrush * Fainting (within the last 30 days) * Other "life threatening illnesses" as per principal investigator and/or study physician's discretion * Pregnancy * Pregnancy (self-reported and urine pregnancy test) * Breastfeeding (determined by self-report) * Women of childbearing potential must be using an acceptable method of contraception * Concurrent participation in another clinical trial. * Inability to read and write in English * Planning to quit smoking or vaping within the next 60 days * A known propylene glycol/vegetable glycerin allergy * Uncomfortable with getting blood drawn * Recent onset or change (worsening) in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular risk factors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco - Tobacco Research Center
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nicotine flux: a new way to gauge how addictive E-Cigarettes are?
- Practice quitting: a new way to help smokers who Aren't ready to stop?
- Can a Quit-Smoking program built for transgender adults help them stop?
- Mindfulness meets wearable tech in a new bid to break the smoking habit
- Could a Nicotine-Free cigarette break the habit?
- Can sleep patterns explain racial gaps in smoking cravings?